topiroxostat
Sign in to saveAlso known as C13H8N6, 4-(5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia. It was approved for use in Japan in June 2013.
Research
139 papers- Topiroxostat-A Safer Uricostatic Drug with Enhanced Renal Protection: A Narrative Review.The Journal of the Association of Physicians of India · 2024
- Topiroxostat ameliorates oxidative stress and inflammation in sepsis-induced lung injury.Zeitschrift fur Naturforschung. C, Journal of biosciences · 2020
- Topiroxostat improves glomerulosclerosis in type 2 diabetic Nagoya Shibata Yasuda mice with early diabetic kidney disease.European journal of pharmacology · 2024
- Protective Effect of Topiroxostat on Myocardial Injury Induced by Lipopolysaccharide.The Journal of surgical research · 2022
- Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.PloS one · 2022
via PubMed
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia. It was approved for use in Japan in June 2013.
Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.
Excerpted from Wikipedia’s “topiroxostat” article, available under the CC BY-SA 4.0 licence.